Vício do Ecrã e Dor Pós-Operatória
Associação Entre o Vício em Smartphone e a Dor Pós-operatória e o Consumo de Analgésicos em Doentes Adultos Submetidos a Rinoplastia Electiva: Um Estudo Observacional Prospectivo
Excessive or problematic smartphone use has become increasingly common and has been associated with various psychological and physical health consequences, including anxiety, depressive symptoms, reduced sleep quality, musculoskeletal pain, and heightened pain perception. Postoperative pain is influenced not only by surgical trauma but also by individual psychological and behavioral characteristics. This prospective observational study aims to investigate whether smartphone addiction levels influence postoperative pain scores and analgesic consumption in patients undergoing elective rhinoplasty surgery.
Visão geral do estudo
Status
Status
Condições
Condições
Descrição detalhada
Problematic smartphone use-often referred to as smartphone addiction-has emerged as a significant behavioral concern worldwide. Prior research has demonstrated associations between excessive smartphone use and anxiety, depression, sleep disturbances, impaired attention, and increased musculoskeletal discomfort. Moreover, psychological factors such as stress, anxiety, and cognitive attention patterns are known to modulate postoperative pain perception.
Individuals with higher levels of smartphone addiction commonly exhibit elevated anxiety, restlessness, and depressive symptoms, which may heighten pain sensitivity and interfere with postoperative pain coping mechanisms. However, current literature includes limited evidence directly examining the relationship between smartphone addiction and postoperative pain outcomes.
This single-center prospective observational study will include adult patients aged 18-45 years undergoing elective rhinoplasty surgery under general anesthesia. Eligible participants will be ASA physical status I-II and without psychiatric disorders, chronic analgesic or psychotropic medication use, communication difficulties, prior rhinoplasty surgery, or additional concurrent surgical procedures.
Preoperative data collection will include demographic variables (age, sex, education level, duration of daily smartphone use). Participants will complete two validated instruments in Turkish: The Smartphone Application-Based Addiction Scale - Turkish Version, The Nomophobia Questionnaire (NMP-Q) - Turkish Version.
Surgical and anesthesia management will follow standardized institutional protocols. Postoperative pain will be assessed using the Visual Analog Scale (VAS) at 1, 6, 12, and 24 hours following surgery. Total analgesic consumption within the first 24 hours will also be recorded.
Participants will be categorized based on their smartphone addiction scores, and postoperative pain outcomes and analgesic consumption will be compared between groups. Additionally, correlation analyses will be performed to explore the association between smartphone addiction levels and perceived postoperative pain.
Sample size was calculated using an effect size derived from a previous study reporting a correlation coefficient of rho = 0.292 between problematic phone use and perceived pain. With a significance level of 0.05 and a statistical power of 80%, a minimum of 91 participants were required. To compensate for an anticipated dropout rate of approximately 10%, the final planned sample size is 100 participants.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Contactos e Locais
Locais de estudo
-
-
Tokat Province
-
Tokat Province, Tokat Province, Turquia (Türkiye), 60100
- Tokat Gaziosmanpasa University
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Sample size was calculated using an effect size derived from a previous study reporting a correlation coefficient of rho = 0.292 between problematic phone use and perceived pain. With a significance level of 0.05 and a statistical power of 80%, a minimum of 91 participants were required. To compensate for an anticipated dropout rate of approximately 10%, the final planned sample size is 100 participants.
Descrição
Inclusion Criteria:
- Adults aged 18-45 years
- Scheduled for elective primary rhinoplasty under general anesthesia
- ASA physical status I-II
- Ability to provide informed consent
Exclusion Criteria:
- History of psychiatric disorders (diagnosed anxiety, depression, bipolar disorder, psychosis)
- Use of chronic analgesic, opioid, sedative, or psychotropic medication
- Previous rhinoplasty or combined surgeries
- Neurological disorders affecting pain perception
- Communication difficulties or inability to complete questionnaires
- Chronic pain syndromes (e.g., fibromyalgia, chronic back pain)
- Intraoperative complications requiring deviation from standard anesthesia
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Número de grupos/coortes
Coortes e Intervenções
Grupo / CoorteGrupo / Coorte |
|---|
|
Patients undergoing elective rhinoplasty
This cohort includes adult patients aged 18-45 years with ASA physical status I-II who are scheduled to undergo elective rhinoplasty under general anesthesia. All participants will complete preoperative assessments, including demographic data and validated Turkish versions of the Smartphone Application-Based Addiction Scale and the Nomophobia Questionnaire (NMP-Q). Postoperative pain scores (VAS) will be recorded at 1, 6, 12, and 24 hours following surgery, along with total analgesic consumption within the first 24 hours. No interventions will be applied as part of the study; the cohort will be observed prospectively |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Postoperative Pain Score (VAS)
Prazo: 1st, 6th, 12th, and 24th postoperative hours.
|
Pain intensity measured using the Visual Analog Scale (0-10) |
1st, 6th, 12th, and 24th postoperative hours.
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Total Analgesic Consumption
Prazo: 24 hours postoperatively
|
The total analgesic consumption within the first 24 postoperative hours, including tramadol administered through patient-controlled analgesia (PCA). |
24 hours postoperatively
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 25-MOBAEK-374
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The data supporting the findings of this study are available from the corresponding author upon reasonable request. Interested researchers may contact the corresponding author via email and provide a brief description of their intended use.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .